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PDZPSMD9 (Proteasome Macropain non-ATPase subunit 9), a proteasomal assembly chaperone, harbors
an uncharacterized PDZ-like domain. Here we report the identiﬁcation of ﬁve novel interacting
partners of PSMD9 and provide the ﬁrst glimpse at the structure of the PDZ-domain, including
the molecular details of the interaction. We based our strategy on two propositions: (a) proteins
with conserved C-termini may share common functions and (b) PDZ domains interact with C-termi-
nal residues of proteins. Screening of C-terminal peptides followed by interactions using full-length
recombinant proteins, we discovered hnRNPA1 (an RNA binding protein), S14 (a ribosomal protein),
CSH1 (a growth hormone), E12 (a transcription factor) and IL6 receptor as novel PSMD9-interacting
partners. Through multiple techniques and structural insights, we clearly demonstrate for the ﬁrst
time that human PDZ domain interacts with the predicted Short Linear Sequence Motif (SLIM) at the
C-termini of the client proteins. These interactions are also recapitulated in mammalian cells.
Together, these results are suggestive of the role of PSMD9 in transcriptional regulation, mRNA pro-
cessing and editing, hormone and receptor activity and protein translation. Our proof-of-principle
experiments endorse a novel and quick method for the identiﬁcation of putative interacting part-
ners of similar PDZ-domain proteins from the proteome and for discovering novel functions.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Almost every cellular pathway involved in the biology and
homeostasis of a eukaryotic organism is regulated by the Ubiquitin
Proteasome System (UPS) [1]. Impairment in the function of UPS
components results in the accumulation of proteins leading to cel-
lular stress and apoptosis [2]. While the role of proteasome in nor-
mal biology and disease is by and large well studied, the precise
mechanism, the sequence and the structural requirements forsubstrate recognition, direct and indirect protein–protein interac-
tions required for recruiting a substrate to the proteasome, remain
obscure [3]. The structure and the domain functions of various 19S
subunits and their role in proteasome dependent and independent
functions are unclear. We recently showed that a 13 residue pep-
tide of the A-helix frommyoglobin acts as an anchor while a ﬂoppy
region, the ‘F-helix’ acts as an initiator of proteasome mediated
ubiquitin independent degradation of apomyoglobin [4]. We iden-
tiﬁed new interacting partners of gankyrin, a chaperone of the pro-
teasome assembly and an oncoprotein by recognizing proteins that
share EEVD, a conserved Short Linear Sequence Motif (SLIM) seen
at the gankyrin and S6 ATPase interface [5]. Interaction between
gankyrin and chloride intracellular channel protein through the
conserved hot spot site enhances the migratory potential of breast
carcinoma cell line. In addition, we demonstrated a role for Sug 1,
an ATPase of the proteasome in transcriptional regulation of MHC
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action in basal and signal induced NF-jB activation via enhanced
proteasomal degradation of IjBa [7]. We show that in this signal-
ing pathway, proteasome bound PSMD9 acts as a subunit acceptor
and hnRNPA1 as a shuttle receptor that recruits IjBa for degrada-
tion. Here, we exploit the presence of PDZ domain in PSMD9, a
non-ATPase subunit, and a chaperone, of proteasome assembly to
identify novel interacting partners and suggest putative functions
of this biologically important molecule.2. Material and methods
2.1. Plasmids
PSMD9 cDNA (Origene Technologies) was ampliﬁed and
ligated into pRSETA vector between BamHI and EcoRI sites.
hnRNPA1 and S14 ribosomal protein cDNA was generated by
RT-PCR from RNA extracted from HEK293 cells. E12, growth hor-
mone and the FN3 domain of IL6 receptor were ampliﬁed from
the cDNA obtained from Harvard Institute of Proteomics.
hnRNPA1 was ligated in pGEX4T1 (GE Amersham). FN3 domain
was cloned in pGEX4T1 between BamHI and XhoI. S14, ribosomal
protein, growth hormone and E12 were cloned in pMALC5
between BamHI and EcoRI sites. Mutations generated by site
directed mutagenesis were conﬁrmed by sequencing. PSMD9
was cloned in pCMV10 3X FLAG between HindIII and EcoRI sites.
In doxycycline inducible pTRIPZ vector, PSMD9 was cloned
between AgeI and EcoRI sites. All the interacting partners of
PSMD9 were cloned in HA-pcDNA3.1 (A gift from Dr. Sorab Dalal,
ACTREC) between BamHI and XhoI sites. Also see primers
(Table S6).2.2. Expression and puriﬁcation of recombinant proteins
All recombinant proteins were expressed in E.coli BL21 DE (3)
using 100 lM IPTG at 20 C for 16 h. His-PSMD9 and its mutants
were puriﬁed by Ni-NTA chromatography (Qiagen); GST, GST-
hnRNPA1, GST-FN3 and its mutants were puriﬁed using glutathi-
one sepharose (GE Amersham); MBP and MBP-S14, E12 and
growth hormone were puriﬁed using amylose resin (NEB), accord-
ing to manufacturer’s protocol.
2.3. ELISA with tetra-peptides
N-terminal biotinylated tetra-peptides were procured from
GenPro Biotech, India, (Biotin-KGG-XXXX, where XXXX represents
the tetra-peptide sequence) and reconstituted to 25 mMwith 100%
DMSO and further diluted to 5 mM with distilled water. Anti-
PSMD9 (Abcam) antibody in 0.1 M sodium carbonate buffer, pH
9.5 was coated on Nunc-Immuno™ MicroWell™ 96 well solid
plates and incubated for 16 h at 4 C. Wells were blocked with
2% BSA in TBST (10 mM Tris pH8, 138 mM NaCl and 0.5% Tween-
20) for 1 h at 37 C. His-tagged PSMD9 or its mutant proteins
(5 lg/ml), diluted in TBST (containing 0.1% BSA) were added and
incubated at 37 C for 1 h. Plates were washed, and biotinylated
peptides (in TBST with 0.1% BSA) were added to the wells and incu-
bated for 1 h at 37 C. The plates were washed with TBST vigor-
ously after each incubation step. Finally, streptavidin alkaline
phosphatase (Sigma), at a dilution of 1:2000 in TBST containing
0.1% BSA was added to all wells. After incubation for 1 h at 37 C,
binding was detected by the addition of para-Nitro phenyl phos-
phate (PNPP) (Bangalore Genei, India), the substrate of alkaline
phosphatase and color developed was read at 405 nm (Spectramax
190, Molecular Devices). Wells that lack PSMD9 and wells that lack
anti-PSMD9 antibody were taken as negative controls.2.4. ELISA for PSMD9-hnRNPA1 and PSMD9-growth hormone
interaction
GST-hnRNPA1, its mutants and GST only (control; 5 lg/ml) or
MBP-growthhormone andMBP only (control; 5 lg/ml)were coated
as described for the PSMD9 antibody (Section3.2). All incubations
were performed as described for the peptide ELISA (Section3.2). Dif-
ferent concentrations of His-tagged PSMD9 or its mutant proteins
were (in TBST containing 0.1% BSA) added to the coated plates. After
incubation, anti-his antibody (Cell Signaling)was added at a dilution
of 1:2000, incubated and washed. HRP conjugated anti-mouse anti-
body (GE Amersham) (at 1:3000 dilution) was then added. After
incubation and washes, HRP substrate TMB (1X) was added to all
the wells. Reaction was stopped using 2 M sulfuric acid before
recording the readings at 450 nm. Wells not coated with GST-
hnRNPA1 andwells inwhich PSMD9 or themutantswere not added
servedasnegativecontrols. For thecompetitionassays, recombinant
his-PSMD9 was incubated with different concentrations of GRRF/
GRRG or SCGF/SCGG/SGGF peptides for 1 h at 37 C and then added
to wells containing GST-hnRNPA1 or MBP-GH respectively.
2.5. In vitro pull down assay
Recombinant GST, GST- hnRNPA1, and its mutants (baits) were
allowed to bind with glutathione sepharose beads (GE Amersham)
in Transport Buffer (TB, 20 mM HEPES pH 7.9, 110 mM potassium
acetate, 5 mM sodium acetate, 0.5 mM EGTA and 1 mM DTT) for
1 h at 4 C. Beads were washed, following which PSMD9 or its
mutants (in TB 0.1% BSA) were incubated with each bait for 4 h
at 4 C. Binding was monitored by Western blot using anti-His
antibody (Cell Signaling). Cell lysates of MBP, MBP-S14, growth
hormone, E12 or their respective C-terminal mutants were allowed
to bind with amylose resin (NEB) in Transport Buffer for 1 h at 4 C.
Further incubations with PSMD9 or mutants were performed as
described above except that anti- His antibody (Cell Signaling)
was used to detect bound PSMD9.
2.6. Homology modeling
There is currently no crystal structure available for PSMD9 pro-
tein. A homology model of PDZ domain of PSMD9 was thus con-
structed using comparative modeling method, by comparing the
sequence of this target protein with sequence of other related pro-
teins (template) for which experimental structures are available.
BLAST search showed that the PDZ domain shares 42% sequence
similarity with PDZ2 domain of harmonin and sequence alignment
between the two reveals that this sequence similarity is distrib-
uted throughout the sequence. Solution structure of PDZ2 domain
of harmonin bound with C-terminal peptide of cadherin23 (PDB
code 2KBS) [8] was chosen as a template for the homology model-
ing. Modeller, a program for comparative protein structure model-
ing by satisfaction of spatial restraints [9] was used for generation
of the homology model. Several homology models were built based
on structural information from the template, and model that
showed good stereochemical property was selected for further use.
2.7. Peptide docking
3D structure of peptides GRRF and SCGF was generated using
Xleap module in Amber11 [10]. Peptide in its extended conforma-
tionwas dockedwith the generatedmodel of PDZ domain of PSMD9
protein. Peptide dockingwas carried out with two different docking
programs, HADDOCK [11] and ATTRACT [12]. For HADDOCK, a bind-
ing site was deﬁned using residues Leu124, Gly125, Gln126, Glu128
and Gln181 within the canonical pocket. No information regarding
the binding site was given while using ATTRACT and a complete
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programs were validated earlier, by docking a set of co-crystallized
peptides into the canonical pocket of the corresponding PDZ
domains, and the docked conformations of each peptide had rmsd
values 1.5–2.5 A with the corresponding experimental structures.
2.8. Molecular dynamics simulations
Generated homology model of PDZ domain, peptide GRRF
(derived from C-terminus of hnRNPA1) - PDZ complex (PDZ-GRRF)
and peptide SCGF – PDZ complexes (PDZ-SCGF) (both the canonical
and non-canonical binding mode) were used as the starting struc-
ture for MD simulations. Mutated structures of the protein Q181G
and thetriple b-sheetmutant L124G/Q126G/E128Gwere also gener-
ated by replacing (mutating) the respective residues in PyMol.
Hydrogen atoms were added to the WT and mutant experimental
structures using the Xleap module of the Amber11 package. N-ter-
minus of the GRRF and SCGF peptide was capped by acetylation
(ACE). Simulation systemswere neutralized by the addition of coun-
ter ions. The neutralized systemwas solvatedwith TIP3P [13] water
molecules to form a truncated octahedral boxwith at least 10 ÅA
0
sep-
arating the solute atoms and the edges of the box. MD simulations
were carried out with the Sander module of the AMBER11 package
in combination with the parm03 force ﬁeld [14]. All systems were
ﬁrst subjected to 100 steps of energy minimization. The protein
was initially harmonically restrained (25 kcal mol1 ÅA
0
2) to the
energy minimized coordinates, and MD simulations were initiated
by heating the system to 300 K in steps of 100 K followed by gradual
removal of the positional restraints, and a 1 ns unrestrained equili-
bration at 300 K. The resulting systemwas used as starting structure
for productionMD run. For each case, three independent (using dif-
ferent initial random velocities) MD simulations were carried out
starting from the well equilibrated structure. Each MD simulation
was carried out for 100 ns and conformations were recorded every
10 ps. All MD simulations were carried out in explicit solvent at
300 K. During all the simulations, the long-range electrostatic inter-
actions were treated with the particle mesh Ewald [15] method
using a real space distance cutoff of 9 ÅA
0
. The settle [16] algorithm
was used to constrain bond vibrations involving hydrogen atoms,
which allowed time step of 2 fs during the simulations. Simulation
trajectorieswere visualized using VMD [17] and ﬁgureswere gener-
ated using PyMol.
2.9. Immunoprecipitation
FLAG-PSMD9 and HA tagged interacting partners were overex-
pressed in HEK293 cells. Lysates were added either to M2-Agarose
(Sigma) or to anti HA-agarose beads and incubated for 3 h at 4 C to
immunoprecipitate the complex. Either anti-HA antibody or anti-
FLAG antibody (Sigma) was used for detection.
2.10. Circular dichroism of PSMD9 and its mutants
Far-UV CD spectrum (Jasco, J815) of PSMD9-WT and its mutant
proteinswere recordedbetween260 nmand190 nmina2 mmpath
length cuvette. A protein concentration of 2 lM, in a volume of
500 ll (10 mM phosphate buffer (pH 7.5)) was used for collecting
data at 20 C.Datawerenormalized toobtainmolar ellipticityvalues
and ﬁtted using Dichroweb’s CONTIN software.
2.11. Tryptophan ﬂuorescence of PSMD9 and mutants
Tryptophan ﬂuorescence of PSMD9-WT and PSMD9-PDZ-
mutants was recorded at a concentration of 1.5 lM. Emission spec-
tra between 310 and 400 nm were collected upon excitation at295 nm with a slit width of 5 nm and scan speed of 50 nm/s using
Fluorolog HORIBA ﬂuorimeter.
2.12. Western blotting
Samples were separated on 15% SDS PAGE gels and Western
blots were performed using standard protocols. Depending on
the protein under study, anti-His antibody (mouse monoclonal,
Cell Signaling), anti-FLAG antibody (rabbit polyclonal, Sigma) or
anti-HA antibody (rabbit polyclonal, Sigma) were used.
3. Results
3.1. A screen for putative PSMD9 interacting partners and validation
using full length proteins
Many methods capitalize on the ability of the PDZ domains to
recognize C-terminal residues in proteins to primarily deﬁne their
binding speciﬁcity [18–22]. Peptide libraries have been created,
and peptides derived from the C-terminus of the human proteome
have been used by various investigators [18,23–25]. We chose C-
terminal peptides of the human proteome as baits to identify novel
interacting partners of PSMD9. Premise for this study is that mod-
iﬁcation-independent, sequence speciﬁc recognition is central to
many biological processes, and rules inherent to this recognition
process can bring together proteins of very different functions
under a master regulator. Chung et al., had classiﬁed proteome
from drosophila/yeast/human by recognizing conserved C-termi-
nal residues in some of these proteins [26]. These C-terminal pep-
tides were tested here for the following reasons. (1) Most high-
throughput studies are optimized for selecting peptides with high
afﬁnity while many protein–protein interactions are of low afﬁnity
and, therefore, are likely to be missed. (2) If the corresponding pro-
tein/proteins were to interact, one could quickly move to associ-
ated functions, and ﬁnally (3) such a guided approach prevents
identiﬁcation of those peptides that are not represented in the
human proteome and, are physiologically irrelevant. Due to ﬁnan-
cial constraints, thirteen among the thirty conserved tetra peptides
from the human proteome were chosen. These sequences differ in
charge, hydrophobicity and size and represent some of the known
sequence speciﬁcity seen with other PDZ domains. AGHM, the C-
terminus of E12 transcription factor, the human homolog of rat
E2, was speciﬁcally included. E12 was shown to interact with
Bridge 1 (homolog of PSMD9 with a PDZ domain) during insulin
signaling [27–29]. We cloned, expressed and puriﬁed human
PSMD9 and used enzyme-linked immunosorbent assay (ELISA),
to test for binding of the peptides. GRRF, SCGF and AGHM peptides
bound to PSMD9 to an appreciable extent with SCGF demonstrat-
ing highest afﬁnity (Fig. 1A and Fig. S1A and B). SCGF and GRRF
resemble class III PDZ peptides with the sequence motif-X-[D/E/
K/R]-X-U where U is hydrophobic, and X is any residue. GRRF
forms the C-terminus of hnRNPA1 isoforms while SCGF belongs
to growth hormone (CSH1; referred from henceforth as GH). To
test if the corresponding full length proteins would interact with
PSMD9, we cloned and expressed the longer isoform of hnRNPA1
as a GST fusion protein, GH and E12 as MBP fusion proteins. PSMD9
was expressed as a His-Tag protein. Afﬁnity pull-down followed by
Western blot showed that the three full length proteins interact
with PSMD9 (Fig. 1B–D). While hnRNPA1 (Fig 1E andTable S4)
and E12 binding (Fig 1C) were clearly affected by simple C-termi-
nal substitution (Phe to Gly), GH binding to PSMD9 was not
affected to any measurable extent (Fig. 1D). Deletion of C-terminal
seven residues compromised binding of GH severely (Fig. 1D) and
not surprisingly those of hnRNPA1 and E12, as well (Fig. 1B and C).
These interactions were further conﬁrmed using ELISA and the
Fig. 1. Identiﬁcation of putative interacting partners of PSMD9, and the importance of C-terminal residues in interaction. (A) Conserved C-terminal motifs in the form of tetra
peptides were tested for binding to PSMD9 using ELISA (see Section2 for details). Values represent mean ± SEM (Standard Error of Mean) from three different experiments
performed in duplicates.(B) Recombinant WT hnRNPA1 or hnRNPA1 C-terminal mutant (F372G or CD7) bound to GST served as baits to pull down PSMD9. (C) Interaction of
recombinant E12 and its C-terminal mutants (MBP-fusions) with PSMD9 (His-tag) were tested by in vitro afﬁnity pull-down using MBP-agarose (see Section2 for details). (D)
Interaction of recombinant GH and its C-terminal mutants (MBP fusions) with PSMD9 was tested by in vitro afﬁnity pull-down using MBP-agarose (see Section2 for details).
(E) Interaction of PSMD9 with hnRNPA1 was monitored by ELISA (see Section2 for details). Data were best ﬁt to one site speciﬁc binding using GraphPad Prism (commercial
software, www.graphpad.com). The dissociation constant (Kd) for the interaction was found to be 1.33 ± 0.04 lM for hnRNPA1. Data from two independent experiments each
done in duplicates is represented as mean ± SD (SD-standard deviation). (F) Interaction of PSMD9 with growth hormone. Data were ﬁt to one site speciﬁc binding using
PRISM. The dissociation constant (Kd) for the interaction was found to be 0.84 ± 0.07 lM for growth hormone. Measurements were done in duplicates and data is represented
as mean ± SD (SD- standard deviation) for two independent experiments. (G) C-terminal peptide GRRF inhibits hnRNPA1-PSMD9 interaction. Prior to its incubation with
hnRNPA1 coated plates, PSMD9 (0.65 lM) was incubated with GRRF or GRRG peptides. (H) C-terminal peptide SCGF and SCGG inhibit interaction of growth hormone with
PSMD9. Prior to incubation with growth hormone, PSMD9 (0.65 lM) was incubated with SCGF or SCGG peptides. Ki for SCGF was calculated to be 36.7 ± 0.29 lM and for
SCGG, it was 35.6 ± 0.24 lM. Data from two independent experiments each done in duplicates is represented as mean ± SD. (I) Interaction of hnRNPA1 and PSMD9 in
mammalian cells. FLAG-tagged PSMD9 or its C-terminal mutant and HA- tagged hnRNPA1 were co-expressed in HEK293 cells. FLAG-PSMD9 was immunoprecipitated using
M2-Agarose beads, followed by Western blot with anti-HA antibody. (J) Growth hormone and PSMD9 interact upon co-expression in mammalian cells. HA-Growth hormone
or its C-terminal mutants and FLAG-PSMD9 were co-expressed in HEK293 cells and interaction was monitored by Co-IP as described in supplementary methods.
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Fig. 2. Importance of Cysteine in growth hormone-PSMD9 interaction. (A) Inter-
action of recombinant GH and its C-terminal mutants F217G, DGF, DCGF and CD7
(MBP fusions) with PSMD9 was tested by in vitro afﬁnity pull-down using MBP-
agarose. (B) ELISA was used to monitor interaction between PSMD9 and GH or its C-
terminal mutants. Data were ﬁt to one site speciﬁc binding using PRISM. The
dissociation constant (Kd) for the interaction of WT growth hormone, DGF and DGF
with PSMD9 was found to be 0.74 ± 0.04 lM, 0.8 ± 0.03 and 2.64 ± 0.02 lM,
respectively. Measurements were done in duplicates and data is represented as
mean ± SD (SD-standard deviation) for two independent experiments (Also see
Table S4). (C) C-terminal peptide SCGF and not SGGF inhibit interaction of growth
hormone with PSMD9. Prior to incubation with growth hormone, PSMD9 (0.65 lM)
was incubated with SCGF or SCGG peptides. Ki for SCGF was calculated to be
36.7 ± 0.29 lM. Data from two independent experiments each done in duplicates is
represented as mean ± SD.
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tion is 1.33 ± 0.16 lM and of PSMD9-GH interaction is
0.74 ± 0.04 lM and DG for the interaction between PSMD9 and
WT-hnRNPA1 or GH were calculated to be 6.9 ± 0.04 and
7.1 ± 0.09 kcal/mol, respectively. Peptide GRRF and not GRRG
inhibited hnRNPA1 binding (Ki of 326.5 ± 0.25 lM) conﬁrming
the importance of C-terminal residues (Fig. 1G) in this interaction.
Again, as seen with the C-terminal substitutions of GH, inhibition
of GH-PSMD9 interaction by SCGG was as good as SCGF and the
Ki values for these peptides were 36.7 ± 0.29 and 35.6 ± 0.24 lM,
respectively (Fig. 1H). These pairwise interactions and the role of
C-terminal residues were conﬁrmed in mammalian cells using
co-immunoprecipitation assays (Fig. 1I and J).
3.2. The ﬁne speciﬁcity of SCG derivatives
Unlike hnRNPA1 GRRG mutant, mutant GH with a C-terminal
substituted SCGG binds to the PDZ domain of PSMD9 and interac-
tion is inhibited only upon deletion of C-terminal residues (D7
mutant). To identify the minimal motif important for GH interac-
tion, we engineered DGF, and DCGF mutants of GH and interaction
with PSMD9 was tested by pull down and ELISA (Fig. 2 A and B and
Table S4). While DGF mutant bound with PSMD9, deletion of one
more residue, Cysteine, DGFC, impaired the interaction. By ELISA,
the estimated Kd values were 0.8 ± 0.02 lM for DGF and
2.6 ± 0.011 lM for DCGF mutant. The % occupancy of GH was unal-
tered in the DGF mutant but was reduced to 45% in the case of
the DCGF mutant. This result emphasizes the importance of P2
residue in interaction with PSMD9. The importance of the P2
Cys was further conﬁrmed by demonstrating the failure of peptide
SGGF to inhibit the binding of GH to PSMD9 (Fig. 2C). As noted
before both SCGF and SCGG can inhibit binding between the two
proteins.
Our results help to clarify some of the observations made earlier
with respect to Nas-2-Rpt5 interaction in yeast (PSMD9 homolog
and the ATPase subunit of the 19S regulatory particle). Here, single
C-terminal residue deletion in Rpt5 did not affect its binding to
Nas-2 that made the authors conclude that the PDZ like domain
of Nas2 may not conﬁrm to the classical description [30]. Based
on our results on human PSMD9 using similar pull down assays,
other comparative studies and quantitative analysis, we show that
the precise role of the C-terminal residues in the interaction is
likely to be context dependent. In the case of hnRNPA1 (GRRF)
and E12 (AGHM), bulk of the binding energy is derived from the
C-terminal residue much like the classical PDZ domains. In GH
with SCGF at the C-terminus, however, the terminal residue is less
important. These differences are also reﬂected in the binding afﬁn-
ity of the three peptides to PSMD9. While GRRF binds weakly (Kd
651.7 ± 76 lM), peptide SCGF binds tightly to PSMD9 (Kd
8.6 ± 1.2 lM). One possible explanation is that these peptides
may bind in different modes or orientations at the binding groove
(discussed below). While results observed with the C-terminal
peptides can be readily extrapolated to protein binding, stable
binding of the full length protein may require additional interac-
tions. It is also likely that, besides the canonical a–b groove, the
protein, may bind elsewhere on PSMD9 perhaps at an allosteric site
while the C-terminal sequence acts as initial recognition element
that docks the protein at the canonical site.
3.3. Role of PDZ domain in interaction: modeling and site directed
mutagenesis
To better understand the role of the C-terminal residues and
PDZ domain in binding and recognition, we modeled the structure
of PDZ and carried out extensive molecular dynamic simulations
and peptide docking studies (supplementary methods). Severaldocking poses were created. Upon visual inspection of all the
docked poses, a peptide-protein complex similar to that seen in
the co-crystals of other PDZ-peptide complex with Phe at the
fourth position was chosen. In this conformation, the peptide binds
in an extended, antiparallel manner through canonical interactions
that extend the beta sheet by an additional strand (Fig. 3A and B).
The hydrophobic side chain of Phe4 of the peptide is deeply buried
in the hydrophobic pocket formed by Leu124 from b2, Val139, from
b3, Leu153 from b4, Ile159, Phe 162, from b4. The peptide further
interacts with the beta sheet mainly through backbone/side chain
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b2 of the PDZ domain (Fig. 2B). In addition, the side chain of Arg2 of
the peptide forms a salt bridge with the side chain of Glu128 from
b2. During MD simulation, the alpha/beta binding groove (canoni-
cal binding site) of apo PDZ showed increased ﬂexibility (Supple-
mentary Fig. S2). The a2/b2 binding pocket was partiallyFig. 3. Model of PDZ-domain of PSMD9 and residues important for interaction. (A) Cartoo
the template. (B) Structure of PDZ domain bound to GRRF. A clear cleft that is bordered b
structures. (C) Mutations of residues in the canonical pocket of PDZ domain [Q181G,
hnRNPA1 (D). Recombinant GH (expressed as MBP fusion) and PSMD9 (expressed as Hi
using protocols described in methods. Mutations in the PDZ domain (as described in (C))
its mutant proteins was detected by ELISA. Three independent experiments each in duplic
(F) Circular dichroism of PSMD9-WT and the PDZ mutants were recorded at 2 lM conc
wavelength. (G) Fluorescence spectra of PSMD9-WT and its mutants were recorded betw
normalized ﬂuorescence intensity against wavelength of emission.deformed/destabilized (either collapses or widens), and is stabi-
lized upon peptide binding. Increased ﬂexibility of PDZ domains
in their apo form have been reported by others [31]. The intrinsic
ﬂexibility of PDZ domains is a key determinant that allows them
to recognize a wide repertoire of peptide ligands. Throughout the
protein-peptide simulation, Phe4 remains deeply buried in then representation of PDZ domain of PSMD9 built using PDZ2 domain of harmonin as
y a-helix and a b-strand can be seen in the PDZ domain similar to ligand bound PDZ
the triple mutant (L124G/Q126G/E128G), L153G and F162G], abrogate binding to
s-tagged) interact in vitro. Complex of PSMD9 or its mutants with GH was isolated
abrogate interaction. (E) WT-hnRNPA1 interaction with recombinant WT-PSMD9 or
ates were performed and data is represented as mean ± SD (SD- standard deviation).
entration between 260 nm and195 nm. Molar residual ellipticity is plotted against
een 310 nm and 410 nm (Excitation wavelength 295 nm). Data are represented as
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PDZ/PDZ-PEP-WT-Top.mpg). Charge-charge interactions between
Arg2 and Glu128 on b2 are preserved during the 100 ns simulation.
The bound conformation of the peptide was further stabilized via
backbone hydrogen bond interactions with residues Leu124,
Gly125, Gln126 and Glu128 from b2 in the canonical binding site.
In the complex where Phe4 was mutated to Gly, the peptide
unbinds from the canonical binding site within 5–10 ns and
doesn’t bind again (Movie 2:http://web.bii.a-star.edu.sg/bmad/
PDZ/PDZ-PEP_GRRG-Top.mpg). Although the peptide stays close
to the canonical site due to charge-charge interactions with the
protein residues, it undergoes translation and rotations that pre-
vent it from rebinding in the canonical interaction mode. Thus,
our MD simulations suggest that the burial of Phe in the hydropho-
bic pocket is crucial for the stabilization of this peptide in its bound
conformation. Based on peptide docking and MD simulations
(Movie 3:http://web.bii.a-star.edu.sg/bmad/PDZ/PDZPEP_L124G_
Q126G_E128G-Top.mpg and Movie 4: http://web.bii.a-star.
edu.sg/bmad/PDZ/PDZ-PEP_Q181G-Top.mpg), three single amino
acid mutations F162G, L153G, Q181G and a triple mutation,
L124G/Q126G/E128G were generated. In vitro pull-down shows
that these mutations affect GH and hnRNPA1 binding to PSMD9
(Fig. 3C and D). Mutation of residue L173 (to Gly), part of the a2
helix, not involved in the interaction, did not affect the binding
of peptide or the proteins (Fig. 3E and Table S1). MD simulations
support this ﬁnding as the L173G PSMD9 mutant maintains the
peptide in a stably bound form (not shown).
These results together, conﬁrm the domain-motif interaction
between PDZ domain of PSMD9 and the C-terminal region of the
interacting proteins. The instability of the peptide-free forms is
reﬂected in the secondary structure of these proteins determined
by circular dichroism. While WT PSMD9 records 49% helicity, the
L173G mutant shows 43% helical structure, Q181G mutant 39%,
L153G mutant 45% and the F162G mutant shows 42% helical
structure (Fig. 3F, Table 1 and Appendix Eq.(1)) [32]. Tryptophan
ﬂuorescence of these mutant proteins is less affected (Fig. 3G).
3.4. Identiﬁcation of putative functional modules regulated by PSMD9
Although GRRF and SCGF were motifs under which several fam-
ily members (12 and 13 respectively) were grouped by Chung
et al., a detailed analysis and further curation using UniProt
data (ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/
knowledgebase/) indicated that there was only one unique protein
under each family. There are four isoforms within the GRRF family
and ten isoforms within the SCGF family (Table S2). We re-ana-
lyzed other 28 families and found that, in the vast majority of
the cases, the proteins grouped under each peptide family are pri-
marily isoforms (Table S2). Although isoforms are homologous in
sequence, their functions can be mutually exclusive or even coun-
teractive [33,34]. To better deﬁne the role of C-terminus in func-
tional grouping beyond isoforms, and predict the modules that
may be regulated by PSMD9, we analyzed C-terminal variants ofTable 1
Fraction of helicity of PSMD9 WT and mutants analyzed by circular dichroism.
Protein [h]222 (deg cm2 d mol1)
PSMD9 WT 17281.7 ± 368.34
L173G 15377.4 ± 327.75
Q181G 13734.7 ± 292.14
Triple mutant L124G/Q126G/E128G 14485.3 ± 308.74
F162G 14863.4 ± 253.25
L153G 16455.94 ± 362.63
* The fraction of a-helix present in PSMD9 and mutants were calculated using the CONT
formula fH = ([h]2223000)/(360003000) (Appendix Eq.(1)) [21], where [h]222 is meGRRF and SCGF from the human proteome. There are ten variants
of GRRF where X is C, E, G I, K, L, N, P, Q or R (Table S3). SCGL at the
C-terminus of IL6 receptor was a single variant of SCGF. We
screened seven variants of GRRF (GRRG was already tested as a
control) i.e., GRRC, GRRE, GRRI, GRRL, GRRN, GRRQ and GRRR as
well as the SCGL peptide for binding to PSMD9 by ELISA (Fig. 4A,
Table S5). Peptides GRRL, GRRI, GRRQ, GRRC, GRRR and SCGL
bound to PSMD9. GRRI and GRRL binding afﬁnity were comparable
to GRRF. GRRI belongs to a hypothetical protein. GRRL belongs to
S14. S14 is part of the ribosome and like hnRNPA1 is an RNA bind-
ing protein also involved in protein translation [35]. GRRC and
GRRR surprisingly bound with 12–14-fold higher afﬁnity than
GRRF. GRRC belongs to endothelial receptor protein and GRRR to
UPF2, a protein involved in mRNA metabolism. Like SCGF, SCGL
(from IL6 receptor) bound to PSMD9 with better afﬁnity than GRRF
or its variants. We tested full length S14 and IL-6 receptor C-termi-
nal domain for binding to PSMD9 using in vitro pull down assay,
and both were found to interact with PSMD9. As in hnRNPA1, C-
terminal substitution abrogated binding of S14 and remarkably
as seen with GH, binding of IL-6 receptor was unaffected by the
C-terminal Gly substitution but was inhibited upon deletion
(Fig. 4B and D). Again, similar to hnRNPA1-PDZ interaction, all
the PSMD9 PDZ mutants L153G, F162G, Q181G and the triple
mutant L124G/Q126G/E128G, either did not recognize or bound
less well to WT S14 and the FN3 domain of the IL6 receptor with
intact C-terminal residues (Fig. 4C and E).
To test whether observed in vitro interactions can be extended
to interactions within the cellular milieu, we cloned and trans-
expressed S14 ribosomal protein and the FN3 domain of IL6 recep-
tor and their respective C-terminal mutants, in HEK293 cells.
Immunoprecipitation results clearly conﬁrm all in vitro observa-
tions (Fig. 4F and G).
4. Discussion
Our results taken together indicate that PSMD9 carries a versa-
tile PDZ domain and interacts with residues at the C-terminus of
proteins that are non-homologous in sequence, but carry a signa-
ture Short Linear Sequence Motif. Although the number of peptides
screened here is limited, substantial information can be inferred
from the binding of peptides and proteins to the PDZ domain of
PSMD9 and their mutant forms. Given that the information on
the structure and functions of PSMD9 (and other 19S subunits) is
minimal, the results reported here are highly signiﬁcant. However,
some amount of speculation drawing support from our own stud-
ies and those from the literature is necessary to appreciate the sig-
niﬁcance of the results.
4.1. On the origin of afﬁnity differences
We had included 8 out of 10 C-terminal variants of GRRF, and
SCGL a single variant of SCGF, from the human proteome and pep-
tide AGHM from transcription factor E12, for their ability toHelicity predicted by CONTIN(%) Helicity predicted by formula*(%)
47.5 ± 0.96 52 ± 0.94
41.93 ± 0.77 47.1 ± 0.8
38 ± 0.72 42.9 ± 0.7
40.13 ± 0.77 44.8 ± 0.7
42.14 ± 0.65 45.8 ± 0.62
45.3 ± 0.84 50.7 ± 0.66
IN software available in DICHROWEB server and the helicity is also predicted by the
an molar residual ellipticity at 222 nm.
Fig. 4. Interaction of PSMD9 with C-terminal variants (from the human proteome) of hnRNPA1 and GH. (A) Binding of peptide variants GRRX to recombinant PSMD9. GRRX
peptide (X = any residue) binding to PSMD9 was detected and measured by ELISA. Values from three experiments done in duplicates are represented as means ± SEM. (B) S14
ribosomal protein interacts with PSMD9 via its C-terminal residues. Complex formed between S14 wild type (MBP fusion), S14 L151G or C-terminal deletion mutant S14CD7
was isolated as described in methods. Any bound PSMD9 (His tagged) was detected using anti-His antibody (C) PDZ domain of PSMD9 is important for interaction with S14
ribosomal protein in vitro. For the in vitro pull-down, MBP-S14 fusion and his-PSMD9 or its mutant proteins were processed as described previously. (D) FN3 domain of IL6
receptor interacts with PSMD9 in vitro. GST-WTFN3, FN3 F365G mutant or C-terminal deletion mutant (FN3CD7) were used to pull down PSMD9 (His-tag) and probed for the
presence PSMD9 using anti–His antibody. (E) PDZ domain of PSMD9 is important for interaction with the FN3 domain in vitro. (F) Interaction of S14 with PSMD9 in
mammalian cells. HA-tagged WTS14 or its C-terminal mutants were co-expressed with FLAG-PSMD9, immunoprecipitated and the complexes were probed for FLAG-PSMD9.
(G) Interaction of the FN3 domain of IL6 receptor with PSMD9 in mammalian cells. HA-tagged FN3 domain or its C-terminal mutants were co-expressed with Flag-PSMD9, co-
immunoprecipitated and bound PSMD9 was detected using anti-Flag antibody.
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rized in Table S3. Based on the afﬁnity of the peptides, these vari-
ants can be classiﬁed into three groups – Group I or low afﬁnity
binders, Group II or high afﬁnity binders and Group III tight binders
or the top ranking peptides. In the Group I peptides, hydrophobic
residues such as F, L, I at P0 provide speciﬁcity. In Group II pep-
tides, Cys or Arg at P0 increases afﬁnity by 10-fold as compared
to that of Group I peptides. These two amino acids seem very dif-
ferent from each other and from the Group I peptides in terms of
their physical properties and binding preference of the PSMD9
PDZ domain seems very intricate. The binding pocket of PSMD9
seems better adapted to bind to residues that are not bulky or
highly hydrophobic explaining the high afﬁnity binding of GRRR
and GRRC. On the other hand, both Cys and Arg show characteris-
tics of hydrophobic residues. For example, based on the hydropho-
bicity index Cys is classiﬁed along with Phe [36–39] and arginine,
although one of the least hydrophobic amino acids, shows very
interesting properties. Arginine solubilizes aggregation prone pro-
teins helps in the elution of proteins bound to phenylsepharose
column and has wide application in the puriﬁcation and solubiliza-
tion of inclusion bodies [40,41]. Arginine like GuHCL interacts with
almost all amino acids and preferentially with aromatic residues
[40], but unlike GuHCl, Arginine is not a denaturant [42]. This
probably explains why these two amino acids like the hydrophobic
residues occupy the P0 position. Arg substitution for a Phe in the
interior of a protein will result in destabilization but less likely to
do so at the protein interface.
Based on binding afﬁnity, peptide AGHM will also fall under the
Group I peptides, and methionine is known to be a hydrophobic
residue. GRRE with a negatively charged C-terminus and GRRG
with a small but relatively hydrophobic residue at P0 do not bind
to PSMD9. These results indicate that P0 residue and not GRR is a
major determinant of binding speciﬁcity in these peptides.
Compared to all peptides tested, the top ranking Group III pep-
tides, SCG variants SCGF and SCGL bind with the highest afﬁnity –
Kd for the two peptides is four to ﬁve times less than the Group II
peptides. The hydrophobicity of the C-terminal residue in SCGF and
SCGL is clearly not important for binding and recognition as it can
be readily replaced by a Gly. It seems that, in this set of peptides,
the P1, P2 or P3 residues are more important for high afﬁnity
interaction. By systematically deleting residues from the C-termi-
nus, we identiﬁed Cys at P2 position to be very important for
interaction. In accordance with these results, peptide SGGF was
unable to inhibit the interaction between GH and PSMD9.
It is clear that, in the absence of high resolution crystal structure
of the complexes coupled with kinetic, thermodynamic studies
using mutant peptides, it would be impossible to precisely deﬁne
the molecular basis of afﬁnity differences and positional occupancy
of residues. In the absence of these details, we will have to consider
different possibilities that may account for the binding preferences
and afﬁnity.
Reports from 20 complex structures of PDZ domains with C-ter-
minal peptides of proteins indicate that the aminoacid at the P0
position has no speciﬁc conformational preference in the Rama-
chandran plot. In contrast the P1, P2 and P3 residues show a
strong preference and occupy either a strand or an extended con-
formation [43]. Such a conformational preference especially of
the P2 residue may explain the high afﬁnity interaction seen with
SCGX peptides. Alternatively, SCGF and SCGL peptides may mimic
the internal sequences in proteins that bind PDZ domains and the
Cys at P2 may occupy the hydrophobic pocket formed by L153
and Phe 162 residues, mutations of which affect interaction. Flex-
ibility in the binding modes is not uncommon to the peptide-PDZ
domain interactions. For e.g., the P(2) residue in some of the
PDZ ligands are known to interact with aB-1 and aB-5 residues
on the PDZ domain [43,44]. These residues normally interact withthe P0 residues in the ligand. In the crystal structure of Dvl2 PDZ
domain bound to a noncanonical C-terminal sequence, P3 residue
was seen to occupy the binding position utilized by a P2 residue
[45]. Secondary structure of the PSMD9 mutant proteins F162G
(42%) and L153G (45%; very close to WT 48%) were not dramati-
cally altered compared to other mutant proteins which bind the
peptide (L173G 42%) or those that do not (Q181G 38%; Table 1).
Three modes of peptide binding to PDZ domains in proteins
GRASP, PDLIM and MAST4 have been identiﬁed. In the structures
of GRASP-peptide complexes, it is striking that the two chains of
the protein bind to the same peptide in two different binding
modes. Comparing these structures, a perpendicular mode, an
intermediate mode – both speculated to be kinetic intermediates-
and a stable canonical binding mode have been described [44]. We
can draw parallels from these studies and propose the following:
there exists a conformational ensemble of peptide-PSMD9 com-
plexes. The Group I peptides, probably frequent the non-canonical
or perpendicular orientation seen with other PDZ binding peptides.
This orientation will rely heavily on the burial of the C-terminal
residue for afﬁnity. The Group II peptides GRRC and GRRR peptides
probably frequent the intermediate population wherein the P0 res-
idue is anchored. Peptides SCGF and SCGL populate the extended
conformation in the canonical mode (although simulations pro-
pose a stable binding in the reverse orientation). The entropy cost
of binding is probably paid for the SCGF and SCGL peptides as
described for other protein derived C-terminal peptides bound to
their cognate PDZ domain that may explain the high afﬁnity
interaction.
In our MD simulation studies, SCGF was unstable in the canon-
ical binding mode but binds stably in a fully extended form, in the
reverse orientation (Supplementary Fig. S3). Reverse binding
modes of peptides have also been reported in literature, where
the same peptide binds in opposite orientation i.e., N0–C0 or C0–N0
termini e.g., peptides binding to chaperone DnaK, Calmodulin
and SH3 proteins [46–48]. If SCGF or SCGL peptides bind in a
reverse orientation with the hydroxyl-group of the Ser residue
substituting for the Phe carboxyl residue, mutation of F162 or
L153 residues to Gly, will affect the binding, as seen in Supplemen-
tary Fig. S4. However, since the mutant peptide SGGF is unable to
bind to PSMD9 or inhibit the binding of GH to PSMD9, the Ser res-
idue seems unimportant for interaction. Therefore, binding of
SCGF/L in the reverse orientation as a probable determinant of high
afﬁnity interaction seems less likely.
4.2. On the number of binding sites and the mechanism of binding
Mutation of the C-terminal Phe in GRRF, or Leu in GRRL or Met
in AGHM, to Gly in the respective peptides or proteins inhibits
interaction. Commensurate with these results, while GRRF compet-
itively inhibits approximately 69% of the binding between
hnRNPA1 and PSMD9 the mutant peptide GRRG, is unable to do
so. However, substitution and even deletion of few C-terminal res-
idues does not completely prevent binding of proteins. In all the
cases, the fractional occupancy (like Vmax in enzyme catalysis) is
maximally affected by the C-terminal mutations while the afﬁnity
per se as determined by Kd (like Km for substrate binding) is less
affected. In addition, the afﬁnity differences between peptide or
protein binding to PSMD9 is large. This difference is especially
striking with the Group I peptides, the Kd of which are in the high
lM range (600 lM) while the proteins bind with low micromolar
afﬁnity (1 lM). This vast discrepancy may be explained by the fol-
lowing: (a) C-terminal residues act primarily as signatures or bar
codes that are read by the PDZ domain of PSMD9; (b) maximal
afﬁnity is contributed by a binding motif elsewhere in the protein
or the binding of extended residues at the N-termini of the protein.
Peptide afﬁnity, however increases only marginally upon extension
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nal sequence of E12, with the tetrapeptide motif AGHM, interacts
approximately two times more strongly than the short tetrapep-
tide AGHM (data not shown); and (c) the C-terminal sequences
are stabilized by the structure of the full length protein. Based on
these possibilities we propose a two state binding model for the
interaction between PSMD9 and its client proteins – an initial weak
recognition phase mediated by the C-terminal residues which act
as speciﬁcity determinants followed by its consolidation via inter-
action of a secondary binding motif. Initial recognition of C-termi-
nal residues in proteins by the PDZ domain may allow binding of
the secondary site to an allosteric pocket on PSMD9 (Supplemen-
tary Fig. S5). These may or may not be accompanied by conforma-
tional changes in the proteins. The binding disparity between
Group II peptides or the SCGF and SCGL peptides and their corre-
sponding proteins although is much less (of the order of 8-fold),
the fractional occupancy of the C-terminal deletion mutant, DCGF
of GH is 45% of WT indicating that the same mechanism is prob-
ably operational. The plasticity of the PDZ domain and contribution
of the overall structure to the binding is well illustrated in [31,49].
The partial loss in afﬁnity upon mutations of residues present in
different secondary structural elements of the PSMD9-PDZ domain
is probably a reﬂection of the same paradigm.
It is also possible that the binding afﬁnities are a reﬂection of
the associated functions of the proteins. For example, we have
demonstrated that hnRNPA1 acts as a novel shuttle receptor [7]
that recruits IjBa for degradation by the proteasome. PSMD9 by
interacting with hnRNPA1 and the 26S proteasome helps in
anchoring IjBa and accelerating degradation. In this process,
hnRNPA1 is likely to be recycled. By analogy, S14 may also act as
a shuttle receptor that recruits proteins like MDM2 for degradation
(Fig. 5B, see Section 4.3 for details) and must itself be released
intact. Therefore, the C-terminus of these proteins may bind
weakly to PSMD9. GH and IL6 receptors are the proposed direct
substrates of the proteasome (Fig. 5D see Section 4.3 for details).
In addition to the polyubiquitin binding, initial recognition of the
C-terminal residues by PSMD9 with high afﬁnity may be very
important for the stable binding of such direct substrates to pro-
vide fatal directionality for degradation (Fig. 5D).
4.3. On the functional annotation of PSMD9 and its role in quality
control by the proteasome
In this third part, we speculate on the probable regulatory role
of PSMD9 by inferring on the role of its interacting partners. It is
interesting that these proteins perform very different functions in
the cell. At ﬁrst glance, these interactions seem unusual, and the
real physiological relevance may not be apparent. But detailed lit-
erature study provides substantial support for the plausible phys-
iological role of these interactions in mammalian cells. hnRNPA1 is
known to interact with IjBa in murine cells, and this interaction
somehow accelerates degradation of IjBa resulting in NF-jB acti-
vation [50]. A possible functional conservation can be expected in
human cells, and one may anticipate PSMD9 to regulate NF-jB sig-
naling via IjBa degradation. In the manuscript that we published
recently, we show that hnRNPA1 is a shuttle receptor that recruits
IjBa for degradation and PSMD9 acts as a subunit acceptor and
anchors hnRNPA1 to facilitate degradation of IjBa by the protea-
some [7]. Association of proteasome with ribosome has been doc-
umented in the literature [51–53]. Whether S14 and PSMD9
interaction provides the structural scaffold for this interaction
and what may be the functional consequence of this interaction
in protein translation will be an interesting future investigation.
In addition, S14 is known to bind to MDM2, which prevents the
ability of this E3 ligase to ubiquitinate p53 thereby preventing pro-
teasomal degradation of p53, leading to stabilization andactivation of p53 [54]. Depending on whether or not the interac-
tion between PSMD9 and S14, S14 and MDM2 are mutually exclu-
sive, PSMD9 may inﬂuence ubiquitination, stability and functions
of p53. By drawing a parallel from our studies on hnRNPA1 and
PSMD9 interaction in IjBa degradation, we provide an alternate
possibility for the fate of MDM2 and p53. We speculate that S14,
similar to hnRNPA1 may also act as a shuttle receptor which
recruits MDM2 for degradation by the proteasome (may be under
similar stress conditions). Proteasome associated PSMD9 may
anchor S14 (like it does hnRNPA1) to facilitate degradation of
MDM2 (like IjBa) by the proteasome.
GRRR as mentioned before belongs to UPF2, yet another protein
involved in RNA metabolism. UPF2 is part of a post-splicing multi-
protein complex which regulate mRNA nuclear export and respon-
sible for the detection of exported mRNAs with truncated open
reading frames, resulting in nonsense-mediated mRNA decay [55].
Two other PSMD9 interacting partners GH (CHS1) and IL6
receptor are implicated in chemokine signaling [56,57]. However
both GH and the IL6 receptor with SCGL at the C-termini created
by alternate splicing are soluble, secreted proteins. In order to be
exported out of the cell, these proteins must follow the ER-Golgi
trafﬁc [58]. Secreted proteins are inserted co-translationally into
the ER lumen. Upon achieving their ﬁnal folded state and post-
translational modiﬁcations, these proteins are transported out
of ER, through Golgi and ﬁnally out of the plasma membrane.
However under stress or stimuli induced signaling, when the load
on ER is more, quality control mechanisms must ensure that mis-
folded proteins are degraded. Misfolded and immature proteins
are retro translocated by ER resident translocon and aided by
ubiquitin or specialized proteins like Kar2p/BiP they are actively
pulled out. These proteins are bound by the ER associated protea-
somes and degraded [59–65]. Here, we speculate that while other
ubiquitin binding proteins on the 19S regulatory complex of the
proteasome may bind to the polyubiquitinated GH or IL6 as clas-
sically demonstrated for other proteins, PSMD9 would trap the
misfolded GH or IL6R (and other such ERAD proteins) via the spe-
ciﬁc interaction of the PDZ domain with the respective C-terminal
motif. Such interaction would prevent their premature release
back into ER, ensure directionality and rapid clearance by the
proteasome. Degradation is likely to occur at a basal rate as a
routine quality control measure. The rate would be accelerated
upon signal induction to truncate and attenuate the signaling
process upon withdrawal of the stimuli or in response to ER
stress. Therefore, PSMD9 may act as a general molecular chaper-
one that exerts quality control.
Soluble IL6R formed by splicing or proteolysis also bind to
gp130 present on cells that lack the IL6 receptors. Soluble IL6R-
IL6 complex is involved in what is called as the ‘trans-signaling’
an important mediator of inﬂammation and chemokine signaling
in cancer [66]. Signaling may be attenuated by the receptor medi-
ated endocytosis [67]. By binding to its receptor, GH may also fol-
low receptor mediated endocytosis. The fate of such proteins
engulfed by the process of endocytosis and how these may encoun-
ter the proteasome is described elegantly [60,68–71]. Some of
these proteins routed by endocytosis may become shared sub-
strates of the ‘cytosolic’ proteasomes and lysosomal enzymes. Dif-
ferent parts of the same sequence may be degraded by these
degradation machineries. Our experiments designed to verify the
binding of these proteins to PSMD9 in HEK293 cells upon co-
expression is justiﬁed as these interactions are likely to be post
endocytosis or post extraction events. Future lines of exciting stud-
ies include the characterization of the subcellular loci of these pro-
teins and their ultimate and probably differential fate at the ‘hands’
of proteasome and lysosomes. GRRC belongs to endothelial recep-
tor protein, yet another type I transmembrane protein, involved in
signaling by EPCR [72].
Fig. 5. Putative functional modules of PSMD9 and the probable role of PSMD9 in proteasome mediated quality control. (A) Role of PSMD9 in IjBa degradation. hnRNPA1 is
assumed to be an adaptor protein or a shuttle receptor that recruits ubiquitinated IjBa to the proteasome by interacting with PDZ-PSMD9 via its C-terminus. PSMD9 acts as
the subunit acceptor that helps to anchor IjBa via hnRNPA1. (B) Probable role of PSMD9 in regulating the stability of p53. S14 interacts with MDM2 and regulates the stability
of p53. PSMD9 may modulate the ability of MDM2 to regulate p53 activity in two different ways (please see the Section 4 for details). (C) PSMD9-E12 interaction may be
relevant for transcriptional coactivation/repression of many genes. PSMD9 may also play a regulatory role in proteasomal degradation of E12 to terminate transcription. (D)
Model showing the probable role of PSMD9 in ER associated proteasomal degradation. Misfolded or aggregated secretory proteins like IL6 receptor and growth hormone are
retro-translocated from ER and to ER associated proteasome for degradation. PSMD9 may help in anchoring the translocated substrate by capturing the C-terminal residues.
N. Sangith et al. / FEBS Open Bio 4 (2014) 571–583 581E12-PSMD9 interaction is likely to inﬂuence transcriptional reg-
ulation (like Bridge-1 in insulin signaling). PSMD9 may act either
as a coactivator or as a repressor of many transcription events.
Whether this regulatory role would involve 19S, or the entire 26S
proteasome again or a proteasome independent role at the chro-
matin remains to be seen.With all these examples, the grand or unifying role of PSMD9
seems to be to ensure quality control and regulate the magnitude
of signaling or transcriptional programs (working model Fig. 5).
The probable mechanism is likely to involve the proteasome and
its proteolytic components. However, other regulatory steps
involving an independent pool of PSMD9 and its interacting part-
582 N. Sangith et al. / FEBS Open Bio 4 (2014) 571–583ners within the protein–protein interaction network cannot be
ruled out.
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Appendix A.
fH ¼ ½h222  3000
 
=ð36000 3000Þ; ð1Þ
where fH is the fraction of helicity, [h]222, where [h]222 is the mean
molar residual ellipticity at 222 nm (deg cm2 d mol1).
Appendix B. Supplementary data
Supplementary data associated with this article can be found, in
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